2024
Structural Basis for p19 Targeting by Anti–IL-23 Biologics: Correlations with Short- and Long-Term Efficacy in Psoriasis
Daniele S, Eldirany S, Damiani G, Ho M, Bunick C. Structural Basis for p19 Targeting by Anti–IL-23 Biologics: Correlations with Short- and Long-Term Efficacy in Psoriasis. JID Innovations 2024, 4: 100261. PMID: 38445231, PMCID: PMC10914523, DOI: 10.1016/j.xjidi.2024.100261.Peer-Reviewed Original ResearchIL-23Clinical efficacyIL-23 inhibitors risankizumabSurface areaLong-term clinical efficacyMolecular propertiesIL-23 inhibitorsSolvent accessible surface areaHydrogen-deuterium exchangeIL-23 p19 subunitAccessible surface areaAssociated with short-Clinical efficacy scorePlaque psoriasisClinical responseP19 subunitCrystallographic experimentsPsoriasis pathogenesisReceptor epitopesInhibitor epitopesPsoriasisLinear regression analysisEfficacyTherapeutic classesBinding affinity
2023
Trends in Oral Antibiotic Use for Acne Treatment: A Retrospective, Population-Based Study in the United States, 2014 to 2016.
Grada A, Armstrong A, Bunick C, Salem R, Feldman S. Trends in Oral Antibiotic Use for Acne Treatment: A Retrospective, Population-Based Study in the United States, 2014 to 2016. Journal Of Drugs In Dermatology 2023, 22: 265-270. PMID: 36877883, DOI: 10.36849/jdd.7345.Peer-Reviewed Original ResearchConceptsOral antibiotic useOral antibioticsAntibiotic useAntibiotic treatmentAcne treatmentHealth care claims dataOral antibiotic treatmentShort study durationIBM MarketScanPrimary outcomeGuideline recommendationsRetrospective studyAcne vulgarisRetrospective analysisClaims dataJ DrugsPatientsStudy durationAmerican AcademyTherapeutic classesSeparate occasionsDay gapMonthsAntibiotic resistanceAntibiotics